Akoya Company Overview, Contact Details & Competitors

Insights

Gathering insights about Akoya…

Similar companies to Akoya

Akoya Tech Stack

Akoya uses 8 technology products and services including HubSpot Analytics, Docker, Selenium, and more. Explore Akoya's tech stack below.

HubSpot Analytics
Analytics
Docker
Containerization
Selenium
Frameworks And Libraries
Taleo
Human Resource Management System
ADP HRMS
Human Resource Management System
jQuery
Javascript Libraries
HubSpot
Marketing Automation
Cloudflare Bot Management
Security

Media & News

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease
Dec 10, 2024 | www.globenewswire.com
Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call.
Nov 14, 2024 | seekingalpha.com
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
Nov 14, 2024 | www.zacks.com
Akoya Biosciences Reports Third Quarter 2024 Financial Results
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024.
Nov 14, 2024 | www.globenewswire.com
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Oct 28, 2024 | www.globenewswire.com
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust
Oct 07, 2024 | www.globenewswire.com
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience.
Oct 03, 2024 | www.globenewswire.com

Akoya's Email Address Formats

Akoya uses at least 1 format(s):

Akoya Email Formats	Example	Percentage
First.Last@akoya.com	John.Doe@akoya.com	46%
First@akoya.com	John@akoya.com	44%
Last@akoya.com	Doe@akoya.com	8%
FirstLas@akoya.com	JohnDoe@akoya.com	2%

Frequently Asked Questions

Where is Akoya's headquarters located?

Akoya's main headquarters is located at 6 Liberty Square #2381 Boston, Massachusetts 02109 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Akoya's stock symbol?

Akoya is a publicly traded company; the company's stock symbol is AKYA.

What is Akoya's official website and social media links?

Akoya's official website is akoya.com and has social profiles on LinkedIn.

How much revenue does Akoya generate?

As of October 2024, Akoya's annual revenue reached $15M.

What is Akoya's NAICS code?

Akoya's NAICS code is 52 - Finance and Insurance.

How many employees does Akoya have currently?

As of October 2024, Akoya has approximately 111 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: P. L.Chief Customer Officer: S.Chief Operating Officer: B. P.. Explore Akoya's employee directory with LeadIQ.

What industry does Akoya belong to?

Akoya operates in the Financial Services industry.

What technology does Akoya use?

Akoya's tech stack includes HubSpot AnalyticsDockerSeleniumTaleoADP HRMSjQueryHubSpotCloudflare Bot Management.

What is Akoya's email format?

Akoya's email format typically follows the pattern of . Find more Akoya email formats with LeadIQ.

When was Akoya founded?

Akoya was founded in 2018.

Insights

Similar companies to Akoya

Mastoloni Pearls

Tasaki

Paspaley

Yoko London

Jewelmer

The Pearl Source

Akoya Tech Stack

Media & News

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Akoya Biosciences Reports Third Quarter 2024 Financial Results

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

Akoya's Email Address Formats

Frequently Asked Questions

Where is Akoya's headquarters located?

What is Akoya's stock symbol?

What is Akoya's official website and social media links?

How much revenue does Akoya generate?

What is Akoya's NAICS code?

How many employees does Akoya have currently?

What industry does Akoya belong to?

What technology does Akoya use?

What is Akoya's email format?

When was Akoya founded?

Akoya

Company Overview

Media & News

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?